APLS

Apellis Pharmaceuticals, Inc.

7 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Apellis Pharmaceuticals has reached a pivotal financial inflection point, transitioning from a cash-burning biotech to a profitable commercial entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline profitability, a closer look at the financials reveals a fragile foundation.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every APLS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between genuine commercial scaling and a strategic rescue. The flip to profitability is a psychological victory for investors, yet the reliance on non-recurring licensing revenue and the heavy concentration of its customer base suggest that the path to sustainable independence remains precarious. The Biogen acquisition serves as the primary catalyst, effectively shifting the investment thesis from operational execution to merger arbitrage. Ultimately, the filing underscores a successful product launch phase for SYFOVRE and EMPAVELI, but highlights the inherent risks of the biotech lifecycle, including high debt loads and legal headwinds. Investors are now weighing the certainty of the $41.00 per share cash offer against the speculative nature of the CVR milestones, which require a massive leap in annual sales to realize full value.

Selected Quarter

Core Takeaway

Apellis has achieved its first quarterly profit and is moving toward a merger with Biogen, shifting the stock from a growth play to a merger arbitrage play.

Investor Lens

The trade-off is between the immediate certainty of the Biogen cash offer and the long-term speculative upside of the CVR sales milestones.

Watch Next

The closing of the Biogen merger in mid-Q2 2026 and the subsequent triggering of CVR milestones.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

bullishMay 7

Achieved first quarterly net profit of $18.7 million.

earnings beat

90%

bullishMay 7

Entered definitive merger agreement with Biogen for $41.00 per share plus CVRs.

acquisition

80%

bullishMay 7

Total revenue grew 61% while operating expenses decreased by 3%.

margin expansion

60%

neutralMay 7

Managing $375M senior secured debt and $93.7M convertible notes maturing Sept 2026.

debt restructure

50%

Filing History

10-QMay 7, 2026

Expand Sequence

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.